secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-09-01T23:59:59+00:00
Accession:  0001193125-22-236516
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines promotes Jack Anders to CFO effective Sept 1, 2022
-----------------------------------------------------------------------

- Jack Anders, age 45, appointed CFO effective immediately; previously SVP Finance and Principal Financial and Accounting Officer.
- Anders joined Revolution Medicines in August 2018; prior roles at Depomed (VP Finance), Elan Pharmaceuticals, Yahoo!, and Novellus Systems.
- He began his career at PricewaterhouseCoopers and holds a B.A. in Economics from UCLA; formerly a CPA.
- Anders will continue as Principal Financial and Accounting Officer; no departure of prior CFO announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522236516/0001193125-22-236516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522236516/d393123d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-236516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer